Oruka Therapeutics Inc. Common Stock (ORKA)
Stock · NASDAQ · Health Care
$71.93as of 10/16/2026
Price chart
Active signals
Resistance level
$82.3
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
ORKA Signal Track Record
How signals performed across all stocks →What ORKA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 24 | -0.3% | 38% | August 14, 2026 |
| Volume Spike | 20 | +5.0% | 65% | September 18, 2026 |
| Bollinger Band Breakdown | 16 | +0.9% | 56% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -0.9% | 29% | December 13, 2024 |
| Any 20-session window (baseline) | +0.5% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phas…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 68
- Website
- orukatx.com/
Fundamentals
- 1-day range
- $73.15$77.89
- Market cap
- $5.94B
- P/E (trailing)
- —
- P/E (forward)
- -25.81
- EPS (trailing)
- $-2.46
- Dividend yield
- —
- Beta
- -0.40
- Avg. volume
- 906.1K
- Dividend pay date
- August 28, 2024
52-week range
$24.88$115.52
Next earnings: November 11, 2026 · EPS estimate $-0.62confirmed
Forecasts
12 analyst ratings
Buy 95%
Hold 5%
Sell 0%
1-year price forecast
High
$200
+178.0%
Median
$155.5
+116.2%
Low
$117
+62.7%
Oruka Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ORKAOruka Therapeutics Inc. Common Stock$71.93▼ 2.63%Market cap $5.94BP/E —$24.88$115.52
- CLDXCelldex Therapeutics Inc.$27.53▼ 4.84%Market cap $3.26BP/E —$22.1$45.14
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
- ACHVAchieve Life Sciences Inc. Common Shares$6.38▼ 8.46%Market cap $672.42MP/E —$2.62$8.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ORKA Oruka Therapeutics Inc. Common Stock | $5.94B | — | $71.93 | ▼ 2.63% | $24.88$115.52 |
| CLDX Celldex Therapeutics Inc. | $3.26B | — | $27.53 | ▼ 4.84% | $22.1$45.14 |
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
| ACHV Achieve Life Sciences Inc. Common Shares | $672.42M | — | $6.38 | ▼ 8.46% | $2.62$8.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS SaysYahoo · 9/24/2026
- ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy DataYahoo · 9/24/2026
- Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price TargetBenzinga · 9/24/2026
- HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price TargetBenzinga · 9/24/2026
- What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For ShareholdersYahoo · 9/24/2026
- The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' DataYahoo · 9/23/2026
- Oruka Therapeutics Says Psoriasis Drug Shows Deepening EfficacyYahoo · 9/23/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 9/23/2026
Insider Activity
Insider Actions →Acquired
38.5K
Disposed
40.4K
- Lawrence Otto Klein · October 1, 2026 · Option Exercise25.0K @ $7.8
- Lawrence Otto Klein · October 1, 2026 · Sale200 @ $84.78
- Lawrence Otto Klein · October 1, 2026 · Sale8.6K @ $84.03
- Lawrence Otto Klein · October 1, 2026 · Sale16.2K @ $83.4
- Arjun Agarwal · September 21, 2026 · Sale533 @ $95.75
- Paul T. Quinlan · September 21, 2026 · Option Exercise10.0K @ $7.8
- Paul T. Quinlan · September 21, 2026 · Sale2.7K @ $95.31
- Paul T. Quinlan · September 21, 2026 · Sale601 @ $94.44
- Paul T. Quinlan · September 21, 2026 · Sale3.8K @ $93.32
- Paul T. Quinlan · September 21, 2026 · Sale2.9K @ $92.37
- Laura Lee Sandler · September 15, 2026 · Sale906 @ $95.71
- Arjun Agarwal · September 15, 2026 · Sale560 @ $95.71
- Lawrence Otto Klein · September 15, 2026 · Sale2.5K @ $95.71
- Joana Goncalves · September 15, 2026 · Option Exercise3.5K @ $6.84
- Joana Goncalves · September 15, 2026 · Sale947 @ $95.71
Institutional Ownership
March 31, 2026
- Total shares held
- 51.37M
- Total value held
- $2.48B
- Institutional holders
- 178
Top holders this quarter
- Unknown7.43M
- Unknown4.15M
- Unknown3.71M
- Unknown3.53M
- Unknown2.67M
- Unknown2.32M
- Unknown2.06M
- Unknown2.03M
- Unknown1.86M
- Unknown1.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.